V172
Total Payments
$3.5M
Transactions
118
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.1M | 44 | 0 |
| 2019 | $2.4M | 74 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.5M | 118 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of V172 in Healthy Younger Participants Ages 18 and 49 Years and Healthy Older Participants Ages 60 and 79 Years | Merck Sharp & Dohme Corporation | $3.3M | 0 |
| Molecular and Microbiome,Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants | Merck Sharp & Dohme Corporation | $143,563 | 0 |
| Impact of multimorbidity and virus type on RSV illness in ambulatory settings | Merck Sharp & Dohme Corporation | $19,452 | 0 |
Top Doctors Receiving Payments for V172
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami, FL | $3.5M | 118 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.5M
- Total Doctors 0
- Transactions 118
About V172
V172 is a drug associated with $3.5M in payments to 0 healthcare providers, recorded across 118 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2019 to 2020. In 2020, $1.1M was paid across 44 transactions to 0 doctors.
The most common payment nature for V172 is "Unspecified" ($3.5M, 100.0% of total).
V172 is associated with 3 research studies, including "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of V172 in Healthy Younger Participants Ages 18 and 49 Years and Healthy Older Participants Ages 60 and 79 Years" ($3.3M).